NCT07134842招募中1 期
Window Studies in Glioblastoma: A Phase I Trial Investigating Neoadjuvant Ipilimumab in Newly Diagnosed Glioblastoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 16
- 试验地点
- 1
- 主要终点
- Best overall objective response rate
研究概览
简要总结
WinGlio is a phase I study investigating neoadjuvant (before surgery) ipilimumab ( a type of immunotherapy drug) in patients with newly diagnosed glioblastoma (a form of brain cancer). Participants will receive up to 2 cycles of ipilimumab prior to the standard of care treatments for this patient group which can include debulking surgery and chemoradiation. The aim of giving the ipilimumab to the participants is to see if it is safe to treat patients with this condition with ipilimumab and also to see if the drug helps to reduce or control the patient's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Radiologically or histologically confirmed, newly diagnosed de-novo supratentorial glioblastoma (including gliosarcoma)
- •Age ≥18 years
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (see appendix 3)
- •Clinically fit for, and appropriate to receive, neoadjuvant ipilimumab followed by standard of care treatment, based on investigator and MDT judgement
- •Adequate organ and bone marrow function:
- •Hb ≥9 g/dL
- •Neutrophils ≥1.5 x 109/L
- •Platelets ≥100 x 109/L
- •Lymphocyte count ≥1.0 x 109/L
- •Adequate renal function:
- •Creatinine clearance of ≥ 50mL/min calculated by Cockroft-Gault equation
- •Adequate liver function:
- •Bilirubin ≤ 1.5 x ULN (except for patients with known Gilbert's Syndrome who may have total bilirubin ≤ 3 x ULN)
- •Aspartate or alanine transferase (AST or ALT) ≤ 2.5 x ULN
- •Life expectancy of greater than 12 weeks
- •Willing to comply with the contraceptive requirements of the trial (see section 6.3.5)
- •Willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures
- •Written informed consent
排除标准
- •Known extracranial metastatic or leptomeningeal disease
- •Prior treatment for glioblastoma other than a biopsy or limited resection leaving residual disease
- •Dexamethasone dose >3mg daily (or equivalent) at the time of starting study treatment
- •Antibiotics received within 30 days prior to starting study treatment, except for prophylactic antibiotics given with surgery
- •Intratumoural or peritumoural haemorrhage deemed significant by the treating clinician
- •Active autoimmune disease apart from:
- •Skin conditions such as psoriasis, vitiligo or alopecia not requiring systemic treatment
- •Type 1 diabetes or thyroid disease, controlled on medication
- •Any evidence of severe or uncontrolled diseases (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease)
- •Known hypersensitivity to ipilimumab or any of its excipients
- •Past medical history of interstitial lung disease, idiopathic pulmonary fibrosis, drug-induced interstitial disease which required steroid treatment or any evidence of clinically active interstitial lung disease.
- •Any condition requiring systemic treatment with corticosteroids (>10mg prednisolone daily or equivalent) or other immunosuppressive medications within 14 days prior to starting study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10mg daily prednisolone or equivalent are permitted in the absence of active autoimmune disease.
- •Treatment with any other investigational agent within 28 days or 5 half lives of the investigational agent (whichever is longer) prior to starting ipilimumab treatment.
- •History of previous cancer within 5 years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and non-melanoma skin lesions
- •Positive serology for Hepatitis B defined as a positive test for HepB surface antigen (HBsAg). Note: patients who are HepB core antibody (HBcAb) positive will only be eligible for the study if the HepB virus deocyribonucleic acid (DNA) test is negative and patients are willing to undergo monthly monitoring for HBV reactivation.
- •Positive serology for Hepatitis C defined as a positive test for HCV antibody
- •Diagnosis of prior immunodeficiency or organ-transplant requiring immunosuppressive therapy or known HIV or acquired immunodeficiency syndrome (AIDS)-related illness
- •History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the subject's participation for the full duration of the study, or is not in the best interest of the subject to participate, in the opinion of the treating investigator
- •Women who are pregnant or breast feeding
研究组 & 干预措施
Interventional
Experimental
All patients will be treated with up to two cycles of ipilimumab prior to their standard treatment. Each cycle will last 21 days.
干预措施: Ipilimumab (3 mg/kg) (Biological)
结局指标
主要结局
Best overall objective response rate
时间窗: Through study completion, an average of 14 months
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
时间窗: From trial registration to 3 months post ipilimumab administration
Safety and tolerability of neoadjuvant ipilimumab as assessed by serious and non-serious adverse events, graded according to CTCAE v5.0
Overall Survival at 12 months post trial registration
时间窗: From trial registration to 1 year post treatment
Feasibility of neoadjuvant ipilimumab
时间窗: Upon the final patient completing treatment
The number of patients and percentage of patients completing neoadjuvant ipilimumab regimen will be reported.
次要结局
- Overall survival at 24 months(From date of registration up to 104 weeks)
- Progression Free Survival(From date of registration up to date of progression)
- Surgical Complications(During surgery)
- Treatment Compliance(Through treatment completion, an average of 42 days)
- Changes in Eastern Cooperative Oncology Group performance status(From baseline to end of 12 month follow up)
- Resection Rate(postprocedural)
- Patient Acceptability(Through treatment completion, average of 42 days)
- Surgeon Acceptability(Baseline)
- Delay in Surgery(Date of registration to date of surgery)
- Changes in Health Related Quality of Life (HRQoL) as measure by EORTC QLQ-C30 and QLQ-BN20(Screening to 3 month follow up)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive GlioblastomaBrain CancerNCT02852655Dana-Farber Cancer Institute60
已完成
1 期
A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called GlioblastomaGlioblastomaNCT05376800Boehringer Ingelheim24
进行中（未招募）
1 期
Safety and Tolerability of Fb-PMT in Recurrent GlioblastomaGlioma, MalignantNCT05226494NanoPharmaceuticals LLC34
进行中（未招募）
1 期
Surgical Nivolumab And Ipilimumab For Recurrent GBMGrade IV AstrocytomaGlioblastomaGBMGlioblastoma MultiformeNCT04606316Patrick Wen, MD63
招募中
1 期
New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a StudyNewly Diagnosed GlioblastomaNCT06622434Assistance Publique - Hôpitaux de Paris35